Effects of HGF on phase II activities and reduced GSH levels in human hepatocytes2-a
| Treatment2-b | Donor | ||||||
|---|---|---|---|---|---|---|---|
| D | E | F | G | H | I | L | |
| UGT | |||||||
| Control | N.D.2-c | N.D. | N.D. | 296 | 285 | 786 | 558 |
| HGF | N.D. | N.D. | N.D. | 316 | 194 | 926 | 664 |
| GST | |||||||
| Control | 202 | 126 | 275 | 312 | 204 | 193 | 346 |
| HGF | 175 | 111 | 274 | 230 | 196 | 234 | 422 |
| GSH | |||||||
| Control | 57.6 | 29.8 | 21.5 | N.D. | N.D. | N.D. | N.D. |
| HGF | 31.4 | 35.8 | 18.3 | N.D. | N.D. | N.D. | N.D. |
↵2-a UGT activity is expressed as picomoles of 4-methylumbellipherone conjugated per milligram of cellular protein and per minute; GST activity is expressed as nanomoles of CDNB conjugated per milligram of cellular protein and per minute; GSH content is expressed as nanomoles per milligram of cellular protein.
↵2-b Human hepatocytes were exposed to 10 ng/ml HGF after 24 hr of culture, and the activities and GSH levels were evaluated 72 hr later.
↵2-c N.D., not determined.